Inspire Investing LLC cut its holdings in shares of United Therapeutics Corporation (NASDAQ:UTHR – Free Report) by 8.1% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 11,088 shares of the biotechnology company’s stock after selling 976 shares during the quarter. Inspire Investing LLC’s holdings in United Therapeutics were worth $6,575,000 as of its most recent SEC filing.
Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Avoro Capital Advisors LLC increased its position in shares of United Therapeutics by 17.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 2,606,060 shares of the biotechnology company’s stock worth $1,269,803,000 after acquiring an additional 383,838 shares during the period. Wellington Management Group LLP boosted its holdings in United Therapeutics by 74.5% in the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock valued at $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. AQR Capital Management LLC grew its stake in United Therapeutics by 29.9% during the 4th quarter. AQR Capital Management LLC now owns 1,281,699 shares of the biotechnology company’s stock worth $624,508,000 after purchasing an additional 295,221 shares in the last quarter. Janus Henderson Group PLC grew its stake in United Therapeutics by 75.1% during the 4th quarter. Janus Henderson Group PLC now owns 796,101 shares of the biotechnology company’s stock worth $387,801,000 after purchasing an additional 341,383 shares in the last quarter. Finally, Darwin Global Management Ltd. purchased a new stake in United Therapeutics during the 3rd quarter worth about $317,617,000. Hedge funds and other institutional investors own 94.08% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research firms have issued reports on UTHR. HC Wainwright increased their price target on United Therapeutics from $600.00 to $660.00 and gave the company a “buy” rating in a research report on Tuesday, March 31st. Cantor Fitzgerald upped their target price on shares of United Therapeutics from $525.00 to $625.00 and gave the stock an “overweight” rating in a research note on Thursday, March 12th. Wells Fargo & Company raised shares of United Therapeutics from an “equal weight” rating to an “overweight” rating and raised their target price for the company from $575.00 to $735.00 in a report on Thursday, May 7th. Raymond James Financial started coverage on shares of United Therapeutics in a research note on Friday, April 10th. They issued an “outperform” rating and a $700.00 price target for the company. Finally, Royal Bank Of Canada lowered their price target on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $619.42.
Insider Activity
In other news, CFO James Edgemond sold 10,000 shares of United Therapeutics stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $558.40, for a total transaction of $5,584,000.00. Following the sale, the chief financial officer owned 18,876 shares in the company, valued at approximately $10,540,358.40. The trade was a 34.63% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 633,218 shares of company stock worth $357,330,714 over the last 90 days. Company insiders own 8.60% of the company’s stock.
United Therapeutics Stock Performance
Shares of NASDAQ UTHR opened at $544.92 on Tuesday. The stock’s 50-day simple moving average is $560.52 and its 200-day simple moving average is $526.39. The firm has a market capitalization of $23.13 billion, a PE ratio of 20.12, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. United Therapeutics Corporation has a fifty-two week low of $272.12 and a fifty-two week high of $609.35.
United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business had revenue of $781.50 million during the quarter, compared to analyst estimates of $797.40 million. During the same period last year, the company earned $6.63 earnings per share. The business’s revenue for the quarter was down 1.6% compared to the same quarter last year. On average, sell-side analysts forecast that United Therapeutics Corporation will post 26.49 earnings per share for the current fiscal year.
United Therapeutics Company Profile
United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.
Featured Articles
- Five stocks we like better than United Therapeutics
- The AI Boom Has a Second Act—And It’s Playing Out in Optics
- Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback?
- 5 Tech Stocks to Buy on the July Pullback
- Is OpenAI’s IPO Delay a Warning for AI Investors?
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Corporation (NASDAQ:UTHR – Free Report).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
